Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer
Abstract Adebrelimab, a novel anti‐PD‐L1 antibody, has been approved by the National Medical Products Administration of China as an intravenous infusion for use in combination with carboplatin and etoposide as first‐line treatment for extensive‐stage small‐cell lung cancer in 2023. A two‐compartment...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Llibre |
| Publicat: |
Wiley,
2024-07-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |